{
    "ticker": "IOVA",
    "name": "Iovance Biotherapeutics, Inc.",
    "description": "Iovance Biotherapeutics, Inc. is a leading biotechnology company focused on the development and commercialization of innovative cell therapies for the treatment of cancer. Founded in 2014 and headquartered in San Carlos, California, Iovance is dedicated to transforming the treatment landscape for patients suffering from various types of cancer through its proprietary tumor-infiltrating lymphocyte (TIL) therapy platform. The company\u2019s lead product, Lifileucel, is an autologous TIL therapy designed to harness the power of the body\u2019s immune system to fight tumors. This innovative approach aims to personalize cancer treatment by utilizing a patient's own immune cells to target and eliminate cancer cells. Iovance is currently advancing its clinical programs for patients with metastatic melanoma, cervical cancer, and non-small cell lung cancer, among others. With a strong commitment to research and development, Iovance is at the forefront of advancing cell therapy as a viable treatment option for cancer patients. The company\u2019s mission is to provide transformative cancer therapies to patients and improve outcomes through cutting-edge science and technology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Carlos, California, USA",
    "founded": "2014",
    "website": "https://www.iovance.com",
    "ceo": "Maria Fardis, Ph.D.",
    "social_media": {
        "twitter": "https://twitter.com/IovanceBio",
        "linkedin": "https://www.linkedin.com/company/iovance-biotherapeutics-inc/"
    },
    "investor_relations": "https://investors.iovance.com",
    "key_executives": [
        {
            "name": "Maria Fardis, Ph.D.",
            "position": "CEO"
        },
        {
            "name": "Jeffrey M. G. Karp, Ph.D.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "Lifileucel"
            ]
        }
    ],
    "seo": {
        "meta_title": "Iovance Biotherapeutics, Inc. | Innovative Cell Therapies for Cancer",
        "meta_description": "Explore Iovance Biotherapeutics, Inc., a leader in developing autologous cell therapies for cancer treatment. Learn about our TIL therapy and commitment to patient care.",
        "keywords": [
            "Iovance",
            "Biotechnology",
            "Cancer Therapy",
            "Cell Therapy",
            "Lifileucel",
            "Tumor-Infiltrating Lymphocytes"
        ]
    },
    "faq": [
        {
            "question": "What is Iovance Biotherapeutics known for?",
            "answer": "Iovance Biotherapeutics is known for its innovative cell therapies, especially its lead product Lifileucel, aimed at treating various cancers."
        },
        {
            "question": "Who is the CEO of Iovance Biotherapeutics?",
            "answer": "Maria Fardis, Ph.D. is the CEO of Iovance Biotherapeutics, Inc."
        },
        {
            "question": "Where is Iovance Biotherapeutics headquartered?",
            "answer": "Iovance Biotherapeutics is headquartered in San Carlos, California, USA."
        },
        {
            "question": "What are Iovance's main products?",
            "answer": "Iovance's main product is Lifileucel, an autologous TIL therapy for cancer treatment."
        },
        {
            "question": "When was Iovance Biotherapeutics founded?",
            "answer": "Iovance Biotherapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "BMY",
        "GILD",
        "AMGN",
        "ZTS"
    ],
    "related_stocks": [
        "VRTX",
        "REGN",
        "ALNY",
        "CRSP"
    ]
}